Cantor Fitzgerald analyst Sarah James downgraded Health Catalyst (HCAT) to Neutral from Overweight with a price target of $4, down from $9. The firm cites the company’s worsening revenue outlook amid multi-year headwinds for the downgrade. Cantor believes the macro environment is too difficult to support growth at Health Catalyst.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT: